|
🐜
|
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
88 auth.
I. Olivotto,
A. Oreziak,
R. Barriales-Villa,
T. Abraham,
A. Masri,
P. García-Pavía,
S. Saberi,
N. Lakdawala,
M. Wheeler,
A. Owens,
M. Kubanek,
W. Wojakowski,
M. Jensen,
J. Gimeno-Blanes,
K. Afshar,
...
J. Myers,
Sheila M. Hegde,
S. Solomon,
A. Sehnert,
David X. Zhang,
Wanying Li,
Mondira Bhattacharya,
J. Edelberg,
C. Waldman,
S. Lester,
Andrew Wang,
Carolyn Y. Ho,
D. Jacoby,
J. Bartunek,
A. Bondue,
E. V. Craenenbroeck,
D. Zemánek,
M. Jensen,
J. Mogensen,
J. Thune,
P. Charron,
A. Hagège,
O. Lairez,
J. Trochu,
C. Axthelm,
H. Duengen,
N. Frey,
V. Mitrović,
M. Preusch,
J. Schulz-Menger,
T. Seidler,
M. Arad,
M. Halabi,
A. Katz,
D. Monakier,
Offir Paz,
S. Viskin,
D. Zwas,
H. Rocca,
M. Michels,
D. Dudek,
Z. Oko-Sarnowska,
N. Cardim,
H. Pereira,
P. G. Pavía,
J. G. Blanes,
R. H. Urbano,
Luis Miguel Rincón Diaz,
P. Elliott,
Z. Yousef,
T. Abraham,
P. Alvarez,
R. Bach,
R. Becker,
L. Choudhury,
D. Fermin,
J. Jefferies,
Christopher Kramer,
N. Lakdawala,
S. Lester,
A. Marian,
Mathew Maurer,
S. Nagueh,
David Owens,
F. Rader,
M. Sherrid,
J. Shirani,
J. Symanski,
A. Turer,
O. Wever-Pinzon,
M. Wheeler,
T. Wong,
M. Yamani
|
9 |
2020 |
9
🐜
|
|
🐜
|
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.
16 auth.
S. Gudbrandsdottir,
H. Birgens,
H. Frederiksen,
B. Jensen,
M. Jensen,
L. Kjeldsen,
T. Klausen,
Herdis Larsen,
H. T. Mourits-Andersen,
C. Nielsen,
...
O. Nielsen,
T. Plesner,
S. Pulczynski,
I. H. Rasmussen,
D. Rønnov‐Jessen,
H. Hasselbalch
|
7 |
2013 |
7
🐜
|
|
🦁
|
Increased circulating platelet–leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count
M. Jensen,
P. de Nully Brown,
B. Lund,
O. Nielsen,
H. Hasselbalch
|
7 |
2001 |
7
🦁
|
|
🦁
|
Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area
M. Jensen,
P. de Nully Brown,
O. Nielsen,
H. Hasselbalch
|
7 |
2000 |
7
🦁
|
|
🦁
|
Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders
M. Jensen,
P. de Nully Brown,
B. Lund,
O. Nielsen,
H. Hasselbalch
|
6 |
2000 |
6
🦁
|
|
🐜
|
A phase II study of vorinostat (MK‐0683) in patients with polycythaemia vera and essential thrombocythaemia
20 auth.
C. Andersen,
M. McMullin,
E. Ejerblad,
S. Zweegman,
C. Harrison,
Savio Fernandes,
D. Bareford,
S. Knapper,
J. Samuelsson,
E. Löfvenberg,
...
O. Linder,
B. Andreasson,
Erik Ahlstrand,
M. Jensen,
O. Bjerrum,
H. Vestergaard,
Herdis Larsen,
T. Klausen,
T. Mourits‐Andersen,
H. Hasselbalch
|
6 |
2013 |
6
🐜
|
|
🐜
|
Whole Blood Transcriptional Profiling Reveals Deregulation of Oxidative and Antioxidative Defence Genes in Myelofibrosis and Related Neoplasms. Potential Implications of Downregulation of Nrf2 for Genomic Instability and Disease Progression
9 auth.
H. Hasselbalch,
M. Thomassen,
C. Hasselbalch Riley,
L. Kjær,
T. Stauffer Larsen,
M. Jensen,
...
O. Bjerrum,
T. Kruse,
V. Skov
|
6 |
2014 |
6
🐜
|
|
🐜
|
Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance.
8 auth.
V. Skov,
T. Larsen,
M. Thomassen,
C. Riley,
M. Jensen,
O. Bjerrum,
...
T. Kruse,
H. Hasselbalch
|
6 |
2012 |
6
🐜
|
|
🐜
|
Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
7 auth.
C. Riley,
M. Jensen,
M. Brimnes,
H. Hasselbalch,
O. Bjerrum,
P. Straten,
...
I. Svane
|
6 |
2011 |
6
🐜
|
|
🐜
|
Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.
8 auth.
V. Skov,
M. Thomassen,
C. Riley,
M. Jensen,
O. Bjerrum,
T. Kruse,
...
H. Hasselbalch,
T. Larsen
|
5 |
2012 |
5
🐜
|
